This Dataset can Ignite An AI Revolution In Cancer Research

Accelerate the Discovery of New Therapeutics with Tahoe Therapeutics’ AI Models for Drug-Cell Interactions

Tahoe Therapeutics, formerly known as Vevo, has made a groundbreaking move in the field of cancer research with the introduction of their latest release, Tahoe 100M. This new dataset is a game-changer in the race to map the human cellular landscape in cancer, offering an unprecedented level of detail and insight into drug-cell interactions.

Tahoe 100M is a massive open-source dataset that includes 100 million single-cell data points and 60,000 experiments, covering 1,100 drug treatments across 50 different cancer types. This dataset represents a 50-fold increase in publicly available perturbational single-cell data, making it the largest single-cell repository in the world.

One of the key features of Tahoe 100M is its inclusion of single cell transcriptomics profiles, which provide detailed gene expression data for each individual cell. These profiles offer a comprehensive view of how each cell responds to drug treatments, giving researchers a more accurate understanding of tumor cell interactions and the impact of cancer heterogeneity on treatment development.

Dr. Johnny Yu, co-founder of Tahoe Therapeutics, highlights the company’s unique “Mosaic Platform” as the technology behind the creation of the dataset. This platform allows for high-throughput testing of drugs across multiple cancer types simultaneously, generating approximately 20,000 measurements across all protein-coding genes per assay. This level of cellular granularity is essential for AI modeling and ensures that the dataset is a valuable resource for researchers.

Tahoe Therapeutics has partnered with the Arc Institute to launch the Arc Virtual Cell Atlas, a comprehensive public database of single-cell level transcriptomic data. This data is free to access and has already been downloaded nearly 11,000 times on the Hugging Face platform. Dr. Hani Goodarzi, scientific co-founder of Tahoe Therapeutics and Core Investigator at the Arc Institute, emphasizes the importance of minimizing batch effects in single-cell data to create a consistent and reliable resource for modeling.

The release of Tahoe 100M represents a significant step forward in understanding cancer vulnerabilities and promoting open data sharing in the scientific community. By providing access to high-quality, large-scale single-cell data, Tahoe Therapeutics is fostering collaboration and paving the way for transformative AI models in drug development and cellular biology.

Overall, Tahoe Therapeutics’ innovative approach to mining drug-cell interactions using AI models has the potential to revolutionize the field of cancer research and accelerate the discovery of new therapeutics. With Tahoe 100M, researchers have a valuable resource at their fingertips to better understand cancer biology and develop more effective treatments.